Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7227060 | 0.83 | POLB (0.56) | L3MBTL1ALDH1A1MAPTGAAPOLB | |
| SCHEMBL1243130 | 0.82 | MAPT (0.46) | L3MBTL1ALDH1A1MAPTGAAPOLB | |
| SCHEMBL3922902 | 0.80 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1MAPTGAAPOLB | |
| SCHEMBL3152711 | 0.79 | PTK2 (0.55) | L3MBTL1ALDH1A1MAPTGAAPOLB | |
| SCHEMBL15202941 | 0.79 | LMNA (0.53) | ALDH1A1MAPTGAAPOLBKMT2A | |
| SCHEMBL29442854 | 0.79 | LMNA (0.53) | ALDH1A1MAPTGAAPOLBKMT2A | |
| SCHEMBL13904227 | 0.79 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1MAPTPOLBKDR | |
| SCHEMBL15017984 | 0.79 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1MAPTPOLBKDR | |
| SCHEMBL17857141 | 0.79 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1MAPTPOLBKDR | |
| SCHEMBL3923269 | 0.77 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1MAPTKDRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317962-A | Imidazopyridazine IL-17 inhibitor compounds | 詹森药业有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118076606-A | Imidazopyridazine IL-17 inhibitor compounds | 詹森药业有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| CN-113286795-B | Imidazo [1,2-b ] pyridazine IL-17A inhibitors | 伊莱利利公司 | 2023-11-03 | — | — | CN | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| CN-115884810-A | Imidazopyridazines as IL-17 modulators | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-2763969-A1 | ETHYNYL DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-8530472-B2 | Ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530472-B2 | Ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530472-B2 | Ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130090347-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090347-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2013050460-A1 | ETHYNYL DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013050460-A1 | ETHYNYL DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20130090347-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2007034278-A2 | FUSED IMIDAZOLE DERIVATIVES AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090347-A1 | ETHYNYL DERIVATIVES | GRM5, GRM1, GRIK5 | L3MBTL1 3858/4885ALDH1A1 3006/4885MAPT 2543/4885 |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | L3MBTL1 2415/4885ALDH1A1 164/4885MAPT 3647/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | L3MBTL1 2415/4885ALDH1A1 164/4885MAPT 3647/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | L3MBTL1 2415/4885ALDH1A1 164/4885MAPT 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.